echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: APOE genotype can significantly affect the rate of clinical progression of Alzheimer's disease

    Neurology: APOE genotype can significantly affect the rate of clinical progression of Alzheimer's disease

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A milestone in Alzheimer's disease (AD) clinical trials is the addition of PET imaging and CSF biomarkers to exclude AD analogs and even design secondary prevention trials for subjects with preclinical AD1 .


    prevention

    However, the success of a trial still depends on the change in the rate of cognitive decline between the test treatment and the placebo, which is hindered by the huge difference in the rate of clinical progress between participants.


    diagnosis

    Therefore, it can be speculated that APOE alleles have different effects on cognition.


    Therefore, it can be speculated that APOE alleles have different effects on cognition.



    The results showed that the increase rate of CDR-SOB in APOEε4 carriers was ≈1.


    The MMSE decline rate of APOEε4 carriers was ≈1.


    The MMSE decline rate of APOEε4 carriers was ≈1.


    The important significance of this study is that it is found that compared with the reference genotype of APOEε3/ε3, APOEε2 and ε4 alleles have opposite effects on the rate of cognitive decline (reduction and acceleration, respectively), which are clinically relevant and basically independent The different effects of APOE alleles on AD and combined pathology.




    neurology.
    org/content/early/2021/03/25/WNL.
    0000000000011894" target="_blank" rel="noopener">Association of Gyrification Pattern, White Matter Changes , and Phenotypic Profile in Patients With Parkinson DiseaseXie Tang, Yuanchao Zhang, Daihong Liu, Yixin Hu, Lingli Jiang, Jiuquan ZhangNeurology Mar 2021, 10.
    1212 / WNL.
    0000000000011894; DOI: 10.
    1212 / WNL.
    0000000000011894

    in This message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.